

100 Pacific St, # 9
Cambridge, MA, 02139

MARIE- LOUISE HUBER

(646) 269-6287
marie.huber@cantab.net

EXPERIENCE

- | | | |
|--|--|--|
| Investment Analyst & Advisor | Huber Consulting | 2012 - Present
<i>New York, NY & Cambridge, MA</i> |
| <ul style="list-style-type: none">• Provide clients with actionable investment analysis in therapeutics and other sectors• Distill and translate technical findings from private investigation teams for hedge fund clients• Identify anomalies within diverse information sources and resolve conflicting information• Published scientific articles in the peer-reviewed Journal of the National Cancer Institute, 2012 (>95 citations), and conducted media outreach to New York Times, Wall Street Journal and Reuters | | |
| Senior Analyst | P. Schoenfeld Asset Management LP | 2007 – 2011
<i>New York, NY</i> |
| <ul style="list-style-type: none">• Senior analyst for pharmaceuticals & biotech, and generalist, at fund with \$4bn assets under management• Conducted quantitative screens and deep due diligence to identify mispriced securities• Pitched high-conviction investment opportunities with anticipated event paths to CEO Peter Schoenfeld• Engaged with portfolio company managements and boards to seek to effect specific changes | | |
| Managing Partner | Forstmann & Co. | 2005 – 2006
<i>New York, NY</i> |
| <ul style="list-style-type: none">• Authored business plans and negotiated founding partnerships for three portfolio companies:<ul style="list-style-type: none">– Exchange-traded structured derivatives, RFID baggage tracking, and telemedicine for correctional facilities• Structured business models to be compelling propositions for all partners and stakeholders | | |
| Co-Founder | Ampere Pharmaceuticals, Inc. | 2003 - 2004
<i>New York, NY</i> |
| <ul style="list-style-type: none">• Co-founded biotech company with Dr James Rothman - Nobel Prize, Physiology or Medicine, 2013 - and Dr Sam Danishefsky - Wolf Prize, 1996• Managed 10 scientists to develop business model for drug discovery platform• Led Series A venture capital funding round in 2004 and negotiated sale of platform to GE Healthcare | | |
| Head of Business Development | Zingy, Inc. | 2001 - 2002
<i>New York, NY</i> |
| <ul style="list-style-type: none">• Co-authored business plan and negotiated licensing agreements with media companies, pre-paid card partnerships with retailers, and artist promotion campaigns with talent management agencies• Raised \$5m angel funding as part of a 2-person team; Zingy was sold to Foreside in 2004 for \$90m | | |
| Business Analyst | McKinsey & Company | 1999 - 2001
<i>London, UK</i> |
| <ul style="list-style-type: none">• Built scenario-based, data-driven valuation models to inform key strategic decisions• Conducted valuation and due diligence support for a private equity firm in the M&A process• Modeled channel economics to monetize nutraceutical ingredients for a biotech company• Analyzed capital and labor flows through aerospace manufacturing process to underpin critical CapEx decisions• Modeled UK rail economics to inform negotiations between government, rail owner and 28 train operators | | |

EDUCATION

- | | | |
|---|--|--------------------|
| MPhil, Bioscience Enterprise | MIT & University of Cambridge | 2002 - 2003 |
| <ul style="list-style-type: none">• Full Scholarship from The Cambridge-MIT Institute• Co-founded Cambridge Laboratory Innovations which won \$110k SMART award from UK government | | |
| BA Hons, Natural Sciences & Biochemistry | University of Cambridge | 1996 – 1999 |
| <ul style="list-style-type: none">• Top 20% of class | | |

SKILLS & CITIZENSHIP

- Skilled with Bloomberg, Factset, CapitalIQ, CatalystTracker, BioMedTracker, Excel, Powerpoint, Keynote, Python
- **German:** Fluent **French, Spanish:** Basic spoken and written skills
- **Citizenships:** UK and Switzerland
- **US Green Card:** Permanent resident after obtaining O-1A visa for extraordinary ability